Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Miki Ueoka

Pulmonary Disease Los Angeles, CA Medical Doctor

NPI 1447784327 CMS profile 9219745

200 Ucla Medical Plz Ste 365B, Los Angeles, CA 90095

Open in the dashboard

General payments

$13,508

58 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miki Ueoka of Los Angeles, CA is reported in the CMS Open Payments database as having received $13,508 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,938 22
2024 General $9,102 12
2023 General $653 3
2022 General $1,543 18
2021 General $249 2
2020 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miki Ueoka
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Miki Ueoka were reported at $1,938. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Miki Ueoka Pulmonary Disease median Middle half National median
2019 $0 $377 $109–$1,340 $163
2020 $25 $230 $56–$907 $114
2021 $249 $269 $68–$1,072 $132
2022 $1,543 $390 $100–$1,457 $149
2023 $653 $419 $114–$1,659 $160
2024 $9,102 $476 $123–$1,818 $164
2025 $1,938 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Intuitive Surgical, Inc. $11,146 32 payments
  2. Medtronic, Inc. $1,329 15 payments
  3. Pulmonx Corporation $280 4 payments
  4. Galvanize Therapeutics, Inc $251 1 payment
  5. Actelion Pharmaceuticals US, Inc. $146 1 payment
  6. Vapotherm Inc $124 1 payment
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $124 1 payment
  8. Olympus America Inc. $59 1 payment
  9. Alexion Pharmaceuticals, Inc. $25 1 payment
  10. GlaxoSmithKline, LLC. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,000 6 payments
  2. Food and Beverage $2,499 39 payments
  3. Education $2,250 1 payment
  4. Travel and Lodging $1,759 12 payments
Products named General payments · program years 2020–2025
  1. Da Vinci Surgical System $10,586 30 payments
  2. ILLUMISITE $1,329 15 payments
  3. DA VINCI SP $500 1 payment
  4. CHARTIS CATHETER $280 4 payments
  5. ZEPHYR DELIVERY CATHETER $280 4 payments
  6. ZEPHYR ENDOBRONCHIAL VALVE $280 4 payments
  7. PULMONX CHARTIS TABLET CONSOLE $280 4 payments
  8. ALIYA SYSTEM $251 1 payment
  9. OPSUMIT $146 1 payment
  10. UPTRAVI $146 1 payment
  11. Other $291 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record